Table 3.

Treatment comparisons to placebo for PVRI, mPAP, and CI in the Down syndrome and non–Down syndrome populations

		Comparison to Placebo (95% CI)
			All Non–Down Syndrome	Non–Down Syndrome
Parameter	Treatment Group	Down Syndrome		Developmentally Able	IPAH/HPAH
PVRI, ratio active/placebo	Low Dose	1.02 (0.62, 1.69) (n = 6)	0.99 (0.80, 1.24) (n = 31)	0.96 (0.74, 1.24) (n = 24)	0.96 (0.67, 1.38) (n = 11)
	Medium Dose	0.81 (0.54, 1.22) (n = 10)	0.82 (0.67, 1.00) (n = 41)	0.78 (0.61, 1.00) (n = 27)	0.75 (0.54, 1.03) (n = 17)
	High Dose	1.11 (0.76, 1.62) (n = 14)	0.64 (0.53, 0.78) (n = 54)	0.56 (0.43, 0.72) (n = 26)	0.67 (0.50, 0.90) (n = 23)
	Combined Dose	0.97 (0.68, 1.38) (n = 30)	0.81 (0.68, 0.95) (n = 126)	0.74 (0.60, 0.91) (n = 75)	0.78 (0.60, 1.02) (n = 51)
mPAP, difference from placebo, mmHg	Low Dose	12.3 (−2.0, 26.5) (n = 6)	−0.99 (−7.55, 5.56) (n = 33)	−2.4 (−10.1, 5.3) (n = 26)	−1.0 (−11.0, 8.9) (n = 12)
	Medium Dose	−2.8 (−14.4, 8.7) (n = 12)	−4.15 (−10.15, 1.85) (n = 43)	−7.7 (−15.3, −0.2) (n = 28)	−2.8 (−11.7, 6.1) (n = 18)
	High Dose	2.8 (−8.4,13.9) (n = 14)	−10.52 (−16.25, −4.79) (n = 57)	−17.2 (−24.9, −9.6) (n = 27)	−7.7 (−16.0, 0.7) (n = 24)
	Combined Dose	4.1 (−5.8, 13.9) (n = 32)	−5.22 (−10.12, −0.32) (n = 133)	−9.6 (−15.7, −3.5) (n = 79)	−3.8 (−11.2, 3.5) (n = 54)
CI, ratio active/placebo	Low Dose	1.02 (0.62, 1.67) (n = 6)	1.08 (0.94, 1.23) (n = 31)	1.10 (0.94, 1.27) (n = 24)	1.07 (0.87, 1.31) (n = 12)
	Medium Dose	0.84 (0.57, 1.24) (n = 10)	1.09 (0.96, 1.23) (n = 41)	1.09 (0.95, 1.27) (n = 27)	1.24 (1.02, 1.50) (n = 17)
	High Dose	1.07 (0.74, 1.55) (n = 14)	1.16 (1.04, 1.30) (n = 55)	1.25 (1.08, 1.45) (n = 27)	1.35 (1.13, 1.62) (n = 23)
	Combined Dose	0.97 (0.69, 1.38) (n = 30)	1.11 (1.01, 1.22) (n = 127)	1.14 (1.01, 1.29) (n = 76)	1.21 (1.03, 1.43) (n = 52)

CI cardiac index, HPAH heritable pulmonary arterial hypertension, IPAH idiopathic pulmonary arterial hypertension, mPAP mean pulmonary artery pressure, PVRI pulmonary vascular resistance index